Sino Biological/CD25/IL2RA Protein, Human, Recombinant (ECD, hFc Tag)/1/10165-H02H
商品编号：
10165-H02H
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
CD25/IL2RA Protein, Human, Recombinant (ECD, hFc Tag): Product Information
Purity
> 90 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
Immobilized human IL2 at 10 μg/mL (100 μl/well) can bind human IL1RA. The EC50 of human IL1RA is 20-100 ng/mL
Protein Construction
A DNA sequence encoding the amino acid residues (Met 1-Cys 213) of the human IL2 receptor α chain (NP_000408.1) precursor was expressed with C-terminal fused human IgG1 Fc region.
Accession#
NP_000408.1
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Glu 22
Molecule Mass
The mature recombinant human IL2Rα/Fc is a disulfide-linked homodimeric protein generated by proteolytic removal of the signal peptide. The reduced monomer consists of 430 amino acids and has a predicted molecular mass of 48.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhIL2Rα/Fc monomer is approximately 72 kDa due to glycosylation.
Formulation
Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
CD25/IL2RA Protein, Human, Recombinant (ECD, hFc Tag): Images
Immobilized human IL2 at 10 μg/mL (100 μl/well) can bind human IL1RA. The EC50 of human IL1RA is 20-100 ng/mL.
CD25/IL2RA Protein, Human, Recombinant (ECD, hFc Tag): Synonyms
CD25 Protein, Human; IDDM10 Protein, Human; IL-2RA Protein, Human; IL2R Protein, Human; p55 Protein, Human; TCGFR Protein, Human
CD25/IL2RA Background Information
CD25 (alpha-chain of the IL-2 receptor, or IL2RA), is a type I transmembrane glycoprotein with a signal peptide, an extracellular region, a transmembrane region, and a cytoplasmic domain. IL2RA is expressed on activated T cells and regulatory T cells and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high-affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covalently with the IL2 receptor beta and gamma chain, and subsequently initiates the intracellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling. The IL2RA (CD25) gene is a substantial component of the high-affinity receptor molecule highly expressed by activated T lymphocytes. Recently, a piece of strong evidence was obtained for the involvement of IL-2RA in conferring susceptibility to type 1 diabetes (T1D). Cancer growth and development are associated with the stimulation of the innate immune system, including enhanced interleukin 2 receptor (IL-2R) expression in immune cells and its shedding into the circulation in a soluble form of SIL-2Ralpha. In most hematological malignancies, including different types of leukemias and lymphomas, SIL-2Ralpha is released directly from the surface of neoplastic cells thus reflecting the tumor bulk, turnover, and activity. Several studies have proved that not only lymphoid cancer cells but also some non-lymphoid cancer cells, express IL-2R on their surface. They include malignant melanoma and carcinomas of the kidney, head and neck, esophagus, and lung. Thus, sIL-2Ralpha is elevated in most proliferative disturbances of the hematopoietic system and many solid tumors.
- Cancer Immunotherapy
- Immune Checkpoint
- Immunotherapy
- Targeted Therapy
Full Name
interleukin 2 receptor, alpha
Research Areas
- Neuroinflammation
- Cancer Drug Targets
Related Pathways
AKT Signaling Pathway
Jak-Stat Signaling Pathway
Autophagy Pathway
Common G-Chain signaling pathway
References
- Driesen J, et al. (2008) CD25 as an immune regulatory molecule expressed on myeloid dendritic cells. Immunobiology. 213(9-10): 849-58.
- Olejniczak K, et al. (2008) Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review. Med Sci Monit. 14(10): RA179-89.
- Chistiakov DA, et al. (2008) The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett. 118(1): 1-5.
- Bien E, et al. (2008) Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers. 13(1): 1-26.
Human CD25/IL2RA Proteins
- CD25/IL2RA Protein, Human, Recombinant (ECD, His Tag)10165-H08H
- CD25/IL2RA Protein, Human, Recombinant (ECD, His & AVI Tag), Biotinylated10165-H27H-B
Mouse CD25/IL2RA Proteins
- CD25/IL2RA Protein, Mouse, Recombinant (ECD, hFc Tag)50292-M02H
- CD25/IL2RA Protein, Mouse, Recombinant (His Tag)50292-M08H
Rat CD25/IL2RA Proteins
- CD25/IL2RA Protein, Rat, Recombinant (His Tag)80074-R08B
Cynomolgus CD25/IL2RA Proteins
- CD25/IL2RA Protein, Cynomolgus, Recombinant (His Tag)90265-C08H
- CD25/IL2RA Protein, Cynomolgus, Recombinant (hFc Tag)90265-C02H
- CD25/IL2RA Protein, Cynomolgus, Recombinant90265-CCCH
Rhesus CD25/IL2RA Proteins
- CD25/IL2RA Protein, Rhesus, Recombinant (ECD, His & AVI Tag), Biotinylated90265-C27H-B
- CUE-101, a Novel HPV16 E7-pHLA-IL-2-Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven MalignanciesAuthorQuayle, SN;Girgis, N;Thapa, DR;Merazga, Z;Kemp, MM;Histed, A;Zhao, F;Moreta, M;Ruthardt, P;Hulot, S;Nelson, A;Kraemer, LD;Beal, DR;Witt, L;Ryabin, J;Soriano, J;Haydock, M;Spaulding, E;Ross, JF;Kiener, PA;Almo, S;Chaparro, R;Seidel, R;Suri, A;Cemerski, S;Pienta, KJ;Simcox, ME;Year2020JournalClin. Cancer Res.Applicationbio-layerPubMed ID: 31964784FoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
